References
- The Bethesda system for reporting cervical/vaginal cytologic diagnoses: revised after the Second National Cancer Institute Workshop. ACTA Cytologica 1993: 37(2): 115–24
- Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991; 265(4): 472–7
- van den Brule AJ, Walboomers JM, Du Maine M, et al. Difference in prevalence of human papillomavirus genotypes in cytomorphologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia. Int J Cancer 1991; 48(3): 404–8
- Young LS, Bevan IS, Johnson MA, et al. The polymerase chain reaction: a new epidemiological tool for investigating cervical human papillomavirus infection. BMJ 1989; 298(6665): 14–8
- Hildesheim A, Schiffinan MH, Gravitt E, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994; 169(2): 235–40
- Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992; 327(18): 1272–8
- McCance D. Human papillomaviruses. In: Cohen M, Hook E, Hitchcock P, eds. Sexually transmitted diseases in the AIDS era: part II. Philadelphia: WB Saunders, 1994: 751–68
- Schneider A, Sawada E, Gissmann L, et al. Human papillomaviruses in women with a history of abnormal Papanicolaou smears and in their male partners. Obstet Gynecol 1987; 69(4): 554–62
- Lorincz AT, Reid R, Jenson AB, et al. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992; 79(3): 328–37
- zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991; 184(1): 9–13
- Durst M, Kleinheinz A, Hotz M, et al. The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours. J Gen Virol 1985; 66(Pt 7): 1515–22
- Baker CC, Phelps WC, Lindgren V, et al. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol 1987; 61(4): 962–71
- Imai Y, Matsushima Y, Sugimura T, et al. Purification and characterization of human papillomavirus type 16 E7 protein with preferential binding capacity to the underphosphorylated form of retinoblastoma gene product. J Virol 1991; 65(9): 4966–72
- Mitchell H, Drake M, Medley G. Prospective evaluation of risk of cervical cancer after cytological evidence of human papilloma virus infection. Lancet 1986; 1(8481): 573–5
- Campion MJ, McCance DJ, Cuzick J, et al. Progressive potential of mild cervical atypia: prospective cytological, colposcopie, and virological study. Lancet 1986; 2(8501): 237–40
- Brinton L. Epidemiology of cervical cancer: overview. In: Munoz N, Bosch F, Shah K, et al, eds. The epidemiology of human papillomavirus and cervical cancer. Lyon, France: The International Agency for Research on Cancer, 1992: 3–23
- American College of Obstetricians and Gynecologists. ACOG Technical Bulletin 1993; 183(Aug): 1–8
- Morrison EA. Natural history of cervical infection with human papillomaviruses. Clin Infect Dis 1994; 18(2): 172–80
- McCance DJ, Campion MJ, Clarkson PK, et al. Prevalence of human papillomavirus type 16 DNA sequences in cervical intraepithelial neoplasia and invasive carcinoma of the cervix. Br J Obstet Gynaecol 1985: 92(11): 1101–5
- Cole H. Diagnostic and therapeutic technology assessment (DATTA): human papillomavirus DNA testing in the management of cervical neoplasia. JAMA 1993: 270(24): 2975–81
- Cox JT, Schifiman MH, Winzelberg AJ, et al. An evaluation of human papillomavirus testing as part of referral to colposcopy clinics. Obstet Gynecol 1992: 80(3 Pt 1): 389–95
- Wright TC, Sun XW, Koulos J. Comparison of management algorithms for the evaluation of women with low-grade cytologic abnormalities. Obstet Gynecol 1995; 85(2): 202–10
- Centers for Disease Control and Prevention. 1993 sexually transmitted diseases treatment guidelines. MMWR 1993; 42(RR-14): 1–102